Clinical Trial

Mechanisms for Vascular Dysfunction and Exercise Tolerance in CF

Study acronym: CF-AOX
Active, Not Recruiting
View on ClinicalTrials.gov →
Summary
Cystic fibrosis has many health consequences. A reduction in the ability to perform exercise in patients with CF is related to greater death rates, steeper decline in lung function, and more frequent lung infections. However, the physiological mechanisms for this reduced exercise capacity are unknown. The investigators recently published the first evidence of systemic vascular dysfunction in patients with CF. Therefore, it is reasonable to suspect that the blood vessels are involved with exercise intolerance in CF. This study will look at how and if oxidative stress contributes to both artery dysfunction and exercise intolerance in CF.
Protocol Amendment History 12 amendments
This ClinicalTrials.gov record has been amended 12 times since 2016-02-19; most recent amendment 2025-01-27.
Status change: Recruiting → Active, Not Recruiting 2022-07-18
Trial Details
NCT Number NCT02690064
Lead Sponsor Augusta University
Conditions Cystic Fibrosis
Enrollment 13 participants
Start Date 2015-04
Primary Completion 2026-12 (estimated)
Study Completion 2027-01 (estimated)
Updated on ClinicalTrials.gov 2025-01-28